Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator.

[1]  S. Taneja.  Re: Association between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer. , 2017, The Journal of urology.

[2]  David C. Miller,et al.  Evaluation of Prostate Cancer Risk Calculators for Shared Decision Making Across Diverse Urology Practices in Michigan. , 2017, Urology.

[3]  M. Meng,et al.  An Update of the American Urological Association White Paper on the Prevention and Treatment of the More Common Complications Related to Prostate Biopsy , 2017, The Journal of urology.

[4]  John T. Wei,et al.  Association Between Combined TMPRSS2: ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer , 2017, JAMA oncology.

[5]  Javed Siddiqui,et al.  Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. , 2016, European urology.

[6]  D. Nieboer,et al.  Prostate cancer risk prediction using the novel versions of the European Randomised Study for Screening of Prostate Cancer (ERSPC) and Prostate Cancer Prevention Trial (PCPT) risk calculators: independent validation and comparison in a contemporary European cohort , 2016, BJU international.

[7]  Sonja Grill,et al.  A simple-to-use method incorporating genomic markers into prostate cancer risk prediction tools facilitated future validation. , 2015, Journal of clinical epidemiology.

[8]  I. Thompson,et al.  Incorporation of detailed family history from the Swedish Family Cancer Database into the PCPT risk calculator. , 2015, The Journal of urology.

[9]  Baris Turkbey,et al.  Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. , 2015, JAMA.

[10]  Yair Lotan,et al.  Can urinary PCA3 supplement PSA in the early detection of prostate cancer? , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  I. Thompson,et al.  Focusing PSA testing on detection of high-risk prostate cancers by incorporating patient preferences into decision making. , 2014, JAMA.

[12]  Lori J Sokoll,et al.  Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer. , 2014, Urology.

[13]  Ziding Feng,et al.  The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator. , 2013, The Journal of urology.

[14]  Yuanyuan Liang,et al.  Updating risk prediction tools: A case study in prostate cancer , 2012, Biometrical journal. Biometrische Zeitschrift.

[15]  Jenny Donovan,et al.  Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group , 2012, World Journal of Urology.

[16]  Jianfeng Xu,et al.  Prostate cancer risk‐associated variants reported from genome‐wide association studies: Meta‐analysis and their contribution to genetic Variation , 2010, The Prostate.

[17]  Ziding Feng,et al.  Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. , 2006, Journal of the National Cancer Institute.

[18]  Freddie C Hamdy,et al.  Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. , 2005, European urology.

[19]  福井 巌,et al.  PSA(prostate specific antigen)と前立腺癌〔含 交見〕 , 1999 .